摘要
目的:观察腺样体术后小儿应用糠酸莫米松喷鼻联合色甘萘甲那敏鼻喷剂的临床疗效。方法:选取2022年7月—2023年7月泉州市儿童医院住院的行腺样体等离子射频消融手术患儿160例,随机分为对照组和观察组,每组80例。对照组应用生理盐水喷鼻及糠酸莫米松喷鼻处理,观察组采用色甘萘甲那敏鼻喷剂喷鼻+糠酸莫米松喷鼻处理。比较两组术后多时间点机体炎症、鼻部总症状评分(TNSS)、匹茨堡睡眠质量指数量表(PSQI)得分,统计不良反应发生情况。结果:观察组术后第21 d的IFN-γ、IL-4均低于对照组,且术后第3、5 d的TNSS评分、PSQI评分低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:腺样体肥大小儿术后早期应用糠酸莫米松喷鼻联合色甘萘甲那敏鼻喷剂能明显获益,可以改善患儿术后的鼻部症状、抑制机体炎症反应程度,提高睡眠质量,并不增加不良反应风险。
Objective:To observe the clinical effect of mometasone furoate nasal spray combined with cromaridine methylamine nasal spray in children after adenoidectomy.Methods:A total of 160 children who underwent adenoid plasma radiofrequency ablation in the Quanzhou Children's Hospital from July 2022 to July 2023 were randomly divided into control group and observation group,with 80 children in each group.The control group was treated with normal saline nasal spray and mometasone furoate nasal spray,while the observation group was treated with carminamine nasal spray+mometasone furoate nasal spray.The scores of body inflammation,total nasal symptom score(TNSS)and Pittsburgh sleep quality index(PSQI)at multiple time points after operation were compared between the two groups,and the incidence of adverse reactions was counted.Results:The levels of IFN-γ and IL-4 in the observation group were lower than those in the control group on the 21st day after operation,and the TNSS score and PSQI score on the 3rd and 5th day after operation were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The early application of mometasone furoate nasal spray combined with cromoganaphenamine nasal spray in children with adenoidal hypertrophy after operation can significantly benefit.It can improve the postoperative nasal symptoms,inhibit the degree of inflammatory response,improve the quality of sleep,and does not increase the risk of adverse reactions.
作者
洪铭沿
徐毅泷
陈秋玉
戴华强
许燕玲
郑天文
HONG Mingyan;XU Yilong;CHEN Qiuyu;DAI Huaqiang;XU Yanling;ZHENG Tianwen(Department of Otolaryngology Head and Neck Surgery,Quanzhou Maternal and Child Health Hospital Children's Hospital,Quanzhou 362000,Fujian,China)
出处
《中国药物滥用防治杂志》
CAS
2024年第11期2114-2116,共3页
Chinese Journal of Drug Abuse Prevention and Treatment
基金
2022年泉州市医疗卫生领域指导性科技计划项目(编号:2022N033S)。
